CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2023		210	298,281
Balance, amount at Dec. 31, 2023	$ 8,098			$ 305,351	$ (297,253)
Public offering sale of common stock, warrants, and prefunded warrants, net of offering costs, shares			421,260
Public offering sale of common stock, warrants and prefunded warrants, net of offering costs, amount	8,010			8,010
Exercise of pre-funded warrants for cash, shares			973,240
Exercise of pre-funded warrants for cash, amount	1			1
Exercise of pre-funded warrants, cashless, shares			205,467
Exercise of pre-funded warrants, amount	1,800
Stock split and fractional shares issued, shares			59,997
Stock-based compensation expense	119			119
Net loss	(3,799)				(3,799)
Balance, shares at Mar. 31, 2024		210	1,958,245
Balance, amount at Mar. 31, 2024	12,429			313,481	(301,052)
Balance, shares at Dec. 31, 2023		210	298,281
Balance, amount at Dec. 31, 2023	8,098			305,351	(297,253)
Net loss	(11,335)
Balance, shares at Sep. 30, 2024		210	3,408,906
Balance, amount at Sep. 30, 2024	97,223			405,811	(308,588)
Balance, shares at Mar. 31, 2024		210	1,958,245
Balance, amount at Mar. 31, 2024	12,429			313,481	(301,052)
Stock-based compensation expense	22			22
Net loss	(3,575)				(3,575)
Balance, shares at Jun. 30, 2024		210	1,958,245
Balance, amount at Jun. 30, 2024	8,876			313,503	(304,627)
Public offering sale of common stock, warrants, and prefunded warrants, net of offering costs, shares			1,450,661
Public offering sale of common stock, warrants and prefunded warrants, net of offering costs, amount	92,293			92,293
Stock-based compensation expense	15			15	(3,961)
Net loss	(3,961)
Balance, shares at Sep. 30, 2024		210	3,408,906
Balance, amount at Sep. 30, 2024	97,223			405,811	(308,588)
Balance, shares at Dec. 31, 2024		210	3,420,906
Balance, amount at Dec. 31, 2024	91,993			406,848	(314,855)
Public offering sale of common stock, warrants, and prefunded warrants, net of offering costs, shares			378,346
Public offering sale of common stock, warrants and prefunded warrants, net of offering costs, amount	23,216			23,216
Exercise of pre-funded warrants, shares			99,189
Exercise of pre-funded warrants, amount	1			1
Exercise of warrants, shares			71,944
Exercise of warrants, amount	347			347
Stock-based compensation expense	4,142			4,142
Net loss	(10,408)				(10,408)
Balance, shares at Mar. 31, 2025		210	3,970,385
Balance, amount at Mar. 31, 2025	109,291			434,554	(325,263)
Balance, shares at Dec. 31, 2024		210	3,420,906
Balance, amount at Dec. 31, 2024	91,993			406,848	(314,855)
Net loss	(37,059)
Balance, shares at Sep. 30, 2025		210	5,907,233
Balance, amount at Sep. 30, 2025	96,211		$ 1	448,124	(351,914)
Balance, shares at Mar. 31, 2025		210	3,970,385
Balance, amount at Mar. 31, 2025	109,291			434,554	(325,263)
Exercise of pre-funded warrants, shares			116,693
Exercise of pre-funded warrants, amount	1			1
Exercise of warrants, shares			61,417
Exercise of warrants, amount	276			276
Stock-based compensation expense	4,609			4,609
Net loss	(10,847)				(10,847)
Balance, shares at Jun. 30, 2025		210	4,148,495
Balance, amount at Jun. 30, 2025	103,330			439,440	(336,110)
Exercise of pre-funded warrants, shares			1,099,400
Exercise of pre-funded warrants, amount	4		$ 1	3
Exercise of warrants, shares			659,338
Exercise of warrants, amount	3,059			3,059
Stock-based compensation expense	5,622			5,622
Net loss	(15,804)				(15,804)
Balance, shares at Sep. 30, 2025		210	5,907,233
Balance, amount at Sep. 30, 2025	$ 96,211		$ 1	$ 448,124	$ (351,914)

TENAX THERAPEUTICS, INC. 10-Q